GI
BIO icon

Gradient Investments’s Bio-Rad Laboratories Class A BIO Stock Holding History

Gradient Investments’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2
Closed -$646 – 1304
2023
Q4 		$646 Hold
2
– – ﹤0.01% 1532
2023
Q3 		$717 Hold
2
– – ﹤0.01% 1469
2023
Q2 		$758 Buy
+2
New +$814 ﹤0.01% 1442
2023
Q1 		– Sell
-3
Closed -$1.26K – 1522
2022
Q4 		$1.26K Buy
+3
New +$1.21K ﹤0.01% 1158
2021
Q3 		– Sell
-1
Closed -$1K – 1145
2021
Q2 		$1K Buy
+1
New +$609 ﹤0.01% 1046
2021
Q1 		– Sell
-2
Closed -$1K – 1153
2020
Q4 		$1K Hold
2
– – ﹤0.01% 1017
2020
Q3 		$1K Buy
+2
New +$1.01K ﹤0.01% 1022
2019
Q1 		– Sell
-29
Closed -$7K – 875
2018
Q4 		$7K Buy
+29
New +$7.78K ﹤0.01% 645

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Gradient Investments's BIO Position: Q1 2024 in Review

Gradient Investments sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2024, closing a stake of 2 shares — an estimated $646 sold.

Gradient Investments first reported a position in BIO in Q4 2018 and held it in 8 quarters. The position peaked at $7K in Q4 2018. 467 funds tracked by Wall St. Rank hold BIO as of Q1 2024.

  • Gradient Investments reported no remaining Bio-Rad Laboratories Class A position as of Q1 2024 after selling out during the quarter.
  • Gradient Investments sold 2 Bio-Rad Laboratories Class A shares in Q1 2024, an estimated $646.
  • Gradient Investments first reported a position in Bio-Rad Laboratories Class A in Q4 2018 and held it in 8 quarters.
  • Gradient Investments's Bio-Rad Laboratories Class A position peaked at $7K in Q4 2018.
  • 467 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2024.

Based on Gradient Investments's 13F filing for Q1 2024, filed 23 Apr 2024.